Unknown

Dataset Information

0

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.


ABSTRACT:

Purpose

Filgrastim (NEUPOGEN®) is the originator recombinant human granulocyte colony-stimulating factor widely used for preventing neutropenia-related infections and mobilizing hematopoietic stem cells. This report presents findings of a systematic literature review and meta-analysis of efficacy and safety of originator filgrastim to update previous reports.

Methods

A literature search of electronic databases, congress abstracts, and bibliographies of recent reviews was conducted to identify English-language reports of clinical trials and observational studies evaluating filgrastim in its US-approved indications up to February 2015. Two independent reviewers assessed titles/abstracts and full texts of publications, and extracted data from studies that compared originator filgrastim vs placebo or no treatment. For outcomes with sufficient homogeneous data reported across studies, meta-analysis was performed and relative risk (RR) determined. Data were summarized descriptively for all other evaluated outcomes.

Results

A total of 1194 unique articles evaluating originator filgrastim were identified, with 25 meeting eligibility criteria for data extraction: 18 randomized controlled trials, 2 nonrandomized clinical trials, and 5 observational studies. In chemotherapy-induced neutropenia (CIN), filgrastim vs placebo or no treatment significantly reduced febrile neutropenia incidence (RR 0.63, 95% CI 0.53-0.75) and grade 3 or 4 neutropenia incidence (RR 0.50, 95% CI 0.37-0.68). The most commonly reported adverse event (AE) with filgrastim was bone pain (RR 2.61, 95% CI 1.29-5.27 in CIN). Additional efficacy and safety outcomes are described within indications.

Conclusions

This systematic literature review and meta-analysis confirms and updates previous reports on the efficacy and safety of originator filgrastim. Bone pain was the commonly reported AE associated with filgrastim use.

SUBMITTER: Dale DC 

PROVIDER: S-EPMC5827957 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.

Dale David C DC   Crawford Jeffrey J   Klippel Zandra Z   Reiner Maureen M   Osslund Timothy T   Fan Ellen E   Morrow Phuong Khanh PK   Allcott Kim K   Lyman Gary H GH  

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20170922 1


<h4>Purpose</h4>Filgrastim (NEUPOGEN<sup>®</sup>) is the originator recombinant human granulocyte colony-stimulating factor widely used for preventing neutropenia-related infections and mobilizing hematopoietic stem cells. This report presents findings of a systematic literature review and meta-analysis of efficacy and safety of originator filgrastim to update previous reports.<h4>Methods</h4>A literature search of electronic databases, congress abstracts, and bibliographies of recent reviews wa  ...[more]

Similar Datasets

| S-EPMC9845441 | biostudies-literature
| S-EPMC10637890 | biostudies-literature
| S-EPMC10674429 | biostudies-literature
| S-EPMC6040046 | biostudies-other
| S-EPMC6050686 | biostudies-literature
| S-EPMC10146040 | biostudies-literature
| S-EPMC11780185 | biostudies-literature
| S-EPMC10834158 | biostudies-literature
| S-EPMC8782811 | biostudies-literature